Thalidomide for Patients With Mild to Moderate Alzheimer's Disease

Status unconfirmed · Phase 2/Phase 3

Conditions studied: Alzheimer's Disease

In brief

This is a 24-week, randomized, double-blind, placebo-controlled study of the effect of thalidomide and placebo on CSF (cerebral spinal fluid) and plasma biomarkers in patients with mild to moderate Alzheimer's disease. This study will evaluate the effects of 24 weeks of treatment with Thalidomide on plasma biomarkers.

Key facts

Study ID

NCT01094340

Run by

Banner Health

People needed

20

Starts

2010-03-01

Expected to finish

2013-01-01

Last updated by the study team

2012-08-08

Who can join

Age: 50 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have a screening diagnosis of Probable Alzheimer's disease according to National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria.
• Subjects must have a Mini-Mental State Examination (MMSE) score of 12-26
• Subject must live at home.
• Must have a caregiver to participate in this study

Where it is running

• Banner Sun Health Research Institute — Sun City, Arizona, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.